.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,225,445

« Back to Dashboard

Claims for Patent: 5,225,445

Title: Phenethanolamine derivatives having .beta..sub.2 -adrenoreceptor selective stimulant action
Abstract:Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12; Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group; R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof. The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients. The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.
Inventor(s): Skidmore; Ian F. (Welwyn, GB2), Lunts; Lawrence H. C. (Broxbourne, GB2), Finch; Harry (Hitchin, GB2), Naylor; Alan (Royston, GB2)
Assignee: Glaxo Group Ltd. (London)
Application Number:07/837,783
Patent Claims: 1. A method of treating a patient suffering from a disease associated with reversible airways obstruction which comprises administering to the patient an effective amount of a compound of general formula (I) ##STR33## wherein m is an integer from 2 to 8 and

n is an integer from 1 to 7 with the proviso that the sum total of m+n is 4 to 12;

Ar represents a phenyl group which may be unsubstituted or substituted by one or two substituents selected from halogen atoms, C.sub.1-3 alkyl and C.sub.1-3 alkoxy groups, or by an alkylenedioxy group of formula --O(CH.sub.2).sub.p O-- where p is 1 or 2; and

R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-3 alkyl group with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;

or a physiologically acceptable salt or solvate thereof.

2. A method according to claim 1, wherein m is 3 and n is 6; or m is 4 and n is 3, 4 or 5; or m is 5 and n is 2, 3, 4 or 5; or m is 6 and n is 2 or 3.

3. A method according to claim 1, wherein the sum total of m+n is 7, 8, 9 or 10.

4. A method according to claim 1, wherein R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a methyl group.

5. A method according to claim 1, Ar represents an unsubstituted phenyl group or a phenyl group substituted by one substituent selected from chlorine and fluorine atoms, methoxy and methyl groups.

6. A method according to claim 1, comprising administering an effective amount of a compound of the general formula (Ia): ##STR34## wherein m is an integer from 3 to 6 and

n is an integer from 2 to 6 with the proviso that the sum total of m+n is 7 to 10 inclusive; and

Ar is phenyl or phenyl substituted by a methyl or methoxy group or a fluorine or chlorine atom; or the physiologically acceptable salts and solvates thereof.

7. A method according to claim 6, wherein R.sup.1 is a hydrogen atom and R.sup.2 is a hydrogen atom or a methyl group.

8. A method according to claim 6, wherein R.sup.1 and R.sup.2, which may be the same or different is each a hydrogen atom or a methyl group, m is 4 or 5, n is 2, 3 or 4 and Ar is phenyl or phenyl substituted by a chlorine or fluorine atom or a methoxy or methyl group.

9. A method according to claim 1, wherein the compound is selected from the group consisting of

4-hydroxy-.alpha..sup.1 -[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[5-(4-phenylbutoxy)pentyl]amino]-methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(2-phenylethoxy)hexyl]-amino]methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(3-phenylpropoxy)pentyl]amino]methyl]-1,3-benzenedimethanol

4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(4-phenylbutoxy)pentyl]amino]methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[1-ethyl-6-(2-phenylethoxy)hexyl]-amino]methyl]-1,3-benzenedimethanol;

.alpha..sup.1 -[[[1,1-dimethyl-6-(2-phenylethoxy)hexyl]amino]-methyl-4-hydroxy-1,3-benze nedimethanol;

.alpha..sup.1 -[[[6-[2-(4-fluorophenyl)ethoxy]-1-methylhexyl]-amino]methyl]-4-hydroxy-1, 3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[6-[3-(4-methoxyphenyl)propoxy]-1methylhexyl]amino]methyl]-1,3-benzened imethanol;

4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methylphenyl)ethoxy]hexyl]amino]methyl]-1,3-benzenedimethanol;

.alpha..sup.1 -[[[6-[2-(3-chlorophenyl)ethoxy]hexyl]amino]methyl]-4-hydroxy-1,3-benzened imethanol;

4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methoxyphenyl)ethoxy]hexyl]amino]-methyl]-1,3-benzenedimethano l;

.alpha..sup.1 -[[[6-[3-(4-fluorophenyl)propoxy]hexyl]amino]-methyl]-4-hydroxy-1,3-benzen edimethanol;

or the physiologically acceptable salts thereof.

10. A method according to claim 1, wherein the disease is asthma or chronic bronchitis.

11. A method of treating a patient suffering from an inflammatory or allergic skin disease, or a condition in which there is an advantage in lowering gastric acidity which method comprises administering to the patient an effective amount of a compound of general formula (I) ##STR35## wherein m is an integer from 2 to 8 and

n is an integer from 1 to 7 with the proviso that the sum total of m+n is 4 to 12;

Ar represents a phenyl group which may be unsubstituted or substituted by one or two substituents selected from halogen atoms, C.sub.1-3 alkyl and C.sub.1-3 alkoxy groups, or by an alkylenedioxy group of formula --O(CH.sub.2).sub.p O-- where p is 1 or 2; and

R.sup.1 and R.sup.2, which may be the same or different, each represents a hydrogen atom or a C.sub.1-3 alkyl group with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4;

or a physiologically acceptable salt or solvate thereof.

12. A method according to claim 11, wherein m is 3 and n is 6; or m is 4 and n is 3, 4 or 5; or m is 5 and n is 2, 3, 4 or 5; or m is 6 and n is 2 or 3.

13. A method according to claim 11, wherein the sum total of m+n is 7, 8, 9 or 10.

14. A method according to claim 11, wherein R.sup.1 and R.sup.1, which may be the same or different, each represents a hydrogen atom or a methyl group.

15. A method according to claim 11, wherein Ar represents an unsubstituted phenyl group or a phenyl group substituted by one substituent selected from chlorine and fluorine atoms, methoxy and methyl groups.

16. A method according to claim 11, comprising administering a compound of the general formula (Ia): ##STR36## wherein m is an integer from 3 to 6 and

n is an integer from 2 to 6 with the proviso that the sum total of m+n is 7 to 10 inclusive; and

Ar is phenyl or phenyl substituted by a methyl or methoxy group or a fluorine or chlorine atom; or the physiologically acceptable salts and solvates thereof.

17. A method according to claim 16, wherein R.sup.1 is a hydrogen atom and R.sup.2 is a hydrogen atom or a methyl group.

18. A method according to claim 16, wherein R.sup.1 and R.sup.2, which may be the same or different is each a hydrogen atom or a methyl group, m is 4 or 5, n is 2, 3 or 4 and Ar is phenyl or phenyl substituted by a chlorine or fluorine atom or a methoxy or methyl group.

19. A method according to claim 11, wherein the compound is selected from the group consisting of

4-hydroxy-.alpha..sup.1 -[[[6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[5-(4-phenylbutoxy)pentyl]amino]-methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(2-phenylethoxy)hexyl]-amino]methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(3-phenylpropoxy)pentyl]amino]methyl]-1,3-benzenedimethanol ;

4-hydroxy-.alpha..sup.1 -[[[1-methyl-5-(4-phenylbutoxy)pentyl]amino]methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[1-ethyl-6-(2-phenylethoxy)hexyl]amino]methyl]-1,3-benzenedimethanol;

.alpha..sup.1 -[[[1,1-dimethyl-6-(2-phenylethoxy)hexyl]amino]-methyl-4-hydroxy-1,3-benze nedimethanol;

.alpha..sup.1 -[[[6-[2-(4-fluorophenyl)ethoxy]-1-methylhexyl]amino]methyl]-4-hydroxy-1,3 -benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[6-[3-(4-methoxyphenyl)propoxy]-1-methyl hexyl]amino]methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[1-methyl-6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol;

4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methylphenyl)ethoxy]hexyl]amino]methyl]-1,3-benzenedimethanol;

.alpha..sup.1 -[[[6-[2-(3-chlorophenyl)ethoxy]hexyl]amino]methyl]-4-hydroxy-1,3-benzened imethanol;

4-hydroxy-.alpha..sup.1 -[[[6-[2-(4-methoxyphenyl)ethoxy]hexyl]amino]-methyl]-1,3-benzenedimethano l;

.alpha..sup.1 -[[[6-[3-(4-fluorophenyl)propoxy]hexyl]amino]-methyl]-4-hydroxy-1,3-benzen edimethanol;

or the physiologically acceptable salts thereof.

20. A method according to claim 11, wherein the patient is suffering from gastric or peptic ulceration.

21. A method according to claim 11, wherein the patient treated is suffering from psoriasis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc